1
|
Machado Kayser J, Petry F, Alijar Souza M, Santin Zanatta Schindler M, Vidor Morgan L, Zimmermann Prado Rodrigues G, Mazon SC, Silva Aguiar GP, Galdino da Rocha Pitta M, da Rocha Pitta I, Leal Xavier L, Girardi Müller L, Gehlen G, Heemann Betti A. Antidepressant effect of PT-31, an α₂-adrenoceptor agonist, on lipopolysaccharide-induced depressive-like behavior in mice. Behav Pharmacol 2024; 35:338-350. [PMID: 39051900 DOI: 10.1097/fbp.0000000000000785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2024]
Abstract
Increasing evidence indicates that neuroinflammation, oxidative stress, and neurotrophic factors play a key role in the pathophysiology of major depressive disorder (MDD). In addition, the attenuation of inflammatory response has been considered a putative mechanism for MDD treatment. PT-31 is an imidazolidine derivative and a putative α₂-adrenoceptor agonist that has previously demonstrated antinociceptive activity. The present study aimed to investigate the effect of PT-31 on depressive-like behavior and lipopolysaccharide-induced neurochemical changes. To this end, mice received intraperitoneally saline or lipopolysaccharide (600 µg/kg), and 5 h postinjection animals were orally treated with saline, PT-31 (3, 10, and 30 mg/kg), or fluoxetine (30 mg/kg). Mice were subjected to the open field test (OFT) 6 and 24 h after lipopolysaccharide administration and to the tail suspension test (TST) 24 h postlipopolysaccharide. Subsequently, animals were euthanized, and brains were dissected for neurochemical analyses. The administration of lipopolysaccharide-induced sickness- and depressive-like behaviors, besides promoting an increase in myeloperoxidase activity and a reduction in brain-derived neurotrophic factor (BDNF) levels. Noteworthy, PT-31 3 mg/kg attenuated lipopolysaccharide-induced decreased locomotor activity 6 h after lipopolysaccharide in the OFT. All tested doses of PT-31 significantly reduced the immobility time of animals in the TST and attenuated lipopolysaccharide-induced increased myeloperoxidase activity in the cortex of mice. Our results demonstrate that PT-31 ameliorates behavioral changes promoted by lipopolysaccharide in OFT and TST, which is possibly mediated by attenuation of the inflammatory response.
Collapse
Affiliation(s)
- Juliana Machado Kayser
- Postgraduate Program in Toxicology and Analytical Toxicology, Health Sciences Institute, Feevale University, Novo Hamburgo
| | - Fernanda Petry
- Molecular Genetics and Ecotoxicology Laboratory, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Maryelen Alijar Souza
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Monica Santin Zanatta Schindler
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Letícia Vidor Morgan
- Pharmacy Course, Health Sciences Area, Community University of Chapecó Region (Unochapecó), Chapecó
| | | | - Samara Cristina Mazon
- Molecular Genetics and Ecotoxicology Laboratory, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Gean Pablo Silva Aguiar
- Molecular Genetics and Ecotoxicology Laboratory, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Marina Galdino da Rocha Pitta
- Nucleus of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife
| | - Ivan da Rocha Pitta
- Nucleus of Research in Therapeutic Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife
| | - Léder Leal Xavier
- Postgraduate Program in Cellular and Molecular Biology, School of Health and Life Sciences, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
| | - Liz Girardi Müller
- Molecular Genetics and Ecotoxicology Laboratory, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
- Postgraduate Program in Environmental Sciences, Sciences and Environmental Area, Community University of Chapecó Region (Unochapecó)
| | - Günther Gehlen
- Postgraduate Program in Toxicology and Analytical Toxicology, Health Sciences Institute, Feevale University, Novo Hamburgo
- Postgraduate Program in Environmental Quality, Health Sciences Institute, Feevale University, Novo Hamburgo
| | - Andresa Heemann Betti
- Postgraduate Program in Toxicology and Analytical Toxicology, Health Sciences Institute, Feevale University, Novo Hamburgo
| |
Collapse
|
2
|
Singh R, Jha D, Dhawan U, Gautam HK, Kumar P. Therapeutic Applications of Self-assembled Indole-3-butanoyl-polyethylenimine Nanostructures. Indian J Microbiol 2022; 62:411-418. [PMID: 35974923 PMCID: PMC9375784 DOI: 10.1007/s12088-022-01015-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 03/06/2022] [Indexed: 12/24/2022] Open
Abstract
This study demonstrates the therapeutic potential of indole-3-butanoyl-polyethylenimine (IBP) nanostructures formed via self-assembly in aqueous system. Dynamic light scattering (DLS) analysis confirmed the formation of the nanostructures in the size range of ~ 194-331 nm. These nanostructures showed commendable antimicrobial activity against wide range of microbes including multi-drug resistant bacteria. Besides, appreciable antioxidant and anti-inflammatory activities were also observed. Results of cytotoxicity studies, performed on normal transformed human embryonic kidney (HEK 293) cells and human red blood cells (hRBCs), revealed almost non-toxic behavior of these nanostructures, however, remarkable toxicity on human breast cancer cells (MCF-7), human osteosarcoma cells (Mg63) and human liver cancer cells (HepG2) was observed. The pre-apoptotic and anti-proliferative activity of IBP nanostructures were confirmed by acridine orange/propidium iodide dual staining assay followed by confocal microscopy and scratch assay on Mg63 cells. Taken together, these results advocate the promising potential of the synthesized IBP nanostructures in the therapeutic applications. Supplementary Information The online version contains supplementary material available at 10.1007/s12088-022-01015-y.
Collapse
Affiliation(s)
- Reena Singh
- Nucleic Acids Research Laboratory, CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110007 India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002 India
| | - Diksha Jha
- Immunology and Infectious Disease Biology Laboratory, CSIR-Institute of Genomics and Integrative Biology, Sukhdev Vihar, New Delhi, 110025 India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002 India
| | - Uma Dhawan
- Department of Biomedical Science, Bhaskaracharya College of Applied Sciences, University of Delhi, Dwarka, New Delhi, 110075 India
| | - Hemant K. Gautam
- Immunology and Infectious Disease Biology Laboratory, CSIR-Institute of Genomics and Integrative Biology, Sukhdev Vihar, New Delhi, 110025 India
| | - Pradeep Kumar
- Nucleic Acids Research Laboratory, CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi, 110007 India
| |
Collapse
|
3
|
Emmanoella Sebulsqui Saraiva T, Rodrigues GZP, Kayser JM, Dallegrave E, Pulz Maus N, Veiverberg A, da Costa Berna G, Schuster AC, Gabriela de Freitas M, Galdino da Rocha Pitta M, da Rocha Pitta I, Gehlen G, Betti AH. Study of the acute and repeated dose 28-day oral toxicity in mice treated with PT-31, a molecule with potential antipsychotic profile. Toxicol Mech Methods 2022; 32:705-715. [PMID: 35410575 DOI: 10.1080/15376516.2022.2065226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Schizophrenia is a psychiatric disorder that affects 1% of the world population and is treated with antipsychotics, which may induce important biochemical and hematological alterations. Since it is necessary to verify the safety of new molecules with antipsychotic potential, the present study aimed to evaluate the oral toxicity of PT-31, a putative α2-adrenoreceptor agonist, after acute (2000 mg/kg) and repeated doses (28 days) gavage treatment, in three different doses: minimum effective dose in animal models (10 mg/kg), twice the dose (20 mg/kg), and four times the dose (40 mg/kg), as recommended by the OECD guidelines. Balb/C female adult mice were used, and biochemical, hematological, and histopathological analyses were performed. PT-31 10 and 20 mg/kg did not cause biochemical alterations related to hepatic and renal toxicity, and neither altered glycemic and lipid profiles. The preclinical dose of PT-31 also did not promote mice histopathological changes in the liver, kidney, and brain. In the hematimetric parameters, PT-31 only increased HGB at 20 mg/kg, and MCH and MCHC at 40 mg/kg. However, all the tested doses of PT-31 showed platelet increase, which must be better investigated. Therefore, further studies are needed to investigate the safety of PT-31 as a potential antipsychotic drug.
Collapse
Affiliation(s)
| | | | - Juliana Machado Kayser
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| | - Eliane Dallegrave
- Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
| | - Nathália Pulz Maus
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| | - Andriele Veiverberg
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| | - Gabriel da Costa Berna
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| | | | | | | | - Ivan da Rocha Pitta
- Research Centre for Therapeutic Innovation. Federal University of Pernambuco, Recife, Pernambuco, Brazil
| | - Günther Gehlen
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| | - Andresa Heemann Betti
- Institute of Health Sciences, Feevale University, Novo Hamburgo, Rio Grande do Sul, Brazil
| |
Collapse
|
4
|
Gouveia ALA, Santos FAB, Alves LC, Cruz-Filho IJ, Silva PR, Jacob ITT, Soares JCS, Santos DKDN, Souza TRCL, Oliveira JF, Lima MDCA. Thiazolidine derivatives: In vitro toxicity assessment against promastigote and amastigote forms of Leishmania infantum and ultrastructural study. Exp Parasitol 2022; 236-237:108253. [PMID: 35381223 DOI: 10.1016/j.exppara.2022.108253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 02/08/2022] [Accepted: 03/30/2022] [Indexed: 11/04/2022]
Abstract
Neglected diseases, such as Leishmaniasis, constitute a group of communicable diseases that occur mainly in tropical countries. Considered a public health problem with limited treatment. Therefore, there is a need for new therapies. In this sense, our proposal was to evaluate in vitro two series of thiazolidine compounds (7a-7e and 8a-8e) against Leishmania infantum. We performed in vitro evaluations through macrophage cytotoxicity assays (J774) and nitric oxide production, activity against promastigotes and amastigotes, as well as ultrastructural analyzes in promastigotes. In the evaluation of cytotoxicity, the thiazolidine compounds presented CC50 values between 8.52 and 126.83 μM. Regarding the evaluation against the promastigote forms, the IC50 values ranged between 0.42 and 142.43 μM. Compound 7a was the most promising, as it had the lowest IC50. The parasites treated with compound 7a showed several changes, such as cell body shrinkage, shortening and loss of the flagellum, intense mitochondrial edema and cytoplasmic vacuolization, leading the parasite to cell inviability. In assays against the amastigote forms, the compound showed a low IC50 (0.65 μM). These results indicate that compound 7a was efficient for both evolutionary forms of the parasite. In silico studies suggest that the compound has good oral bioavailability. These results show that compound 7a is a potential drug candidate for the treatment of Leishmaniasis.
Collapse
Affiliation(s)
- Allana L A Gouveia
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - Fábio A B Santos
- Aggeu Magalhães Institut. Oswaldo Cruz Foundation (IAM-FIOCRUZ), 50670-420, Recife, PE, Brazil
| | - Luiz C Alves
- Aggeu Magalhães Institut. Oswaldo Cruz Foundation (IAM-FIOCRUZ), 50670-420, Recife, PE, Brazil
| | - Iranildo José Cruz-Filho
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - Paula R Silva
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - Iris T T Jacob
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - José Cleberson S Soares
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - Dayane K D N Santos
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil
| | - Tulio Ricardo C L Souza
- Rural University of Pernambuco, Academic Unit of Belo Jardim, 55156-580, Belo Jardim, PE, Brazil
| | - Jamerson F Oliveira
- University for the International Integration of Afro-Brazilian Lusophony (UNILAB), 62790-970, Redenção, CE, Brazil
| | - Maria do Carmo A Lima
- Federal University of Pernambuco, Department of Antibiotics, Center for Biosciences, 50.670-420, Recife, PE, Brazil.
| |
Collapse
|
5
|
Queiroz CM, de Oliveira Filho GB, Espíndola JWP, do Nascimento AV, Aliança ASDS, de Lorena VMB, Feitosa APS, da Silva PR, Alves LC, Leite ACL, Brayner FA. Thiosemicarbazone and thiazole: in vitro evaluation of leishmanicidal and ultrastructural activity on Leishmania infantum. Med Chem Res 2020. [DOI: 10.1007/s00044-020-02619-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Mirasheh MH, Zohrehvand MR, Kazemi R, Bahari Z, Bahrami F, Jangravi Z, Graily M. The Analgesic and Anxiolytic Activity of Resveratrol Mediated by Different Sub-Types of α-Adrenoceptors of Anterior Cingulate Cortex Following Neuropathic Pain in Male Rats. ACTA ACUST UNITED AC 2020. [DOI: 10.30699/jambs.28.129.183] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
PT-31, a putative α2-adrenoceptor agonist, is effective in schizophrenia cognitive symptoms in mice. Behav Pharmacol 2019; 30:574-587. [DOI: 10.1097/fbp.0000000000000494] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
de O Cardoso J, da Silva BF, Venâncio T, da Rocha Pitta MG, da R Pitta I, Peccinini RG, Oliveira RV. Study of the in vitro metabolic profile of a new α 2-adrenergic agonist in rat and human liver microsomes by using liquid chromatography-multiple-stage mass spectrometry and nuclear magnetic resonance. J Pharm Biomed Anal 2019; 172:67-77. [PMID: 31029802 DOI: 10.1016/j.jpba.2019.03.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 03/26/2019] [Accepted: 03/30/2019] [Indexed: 10/27/2022]
Abstract
A potent synthetic α2-adrenergic agonist called PT-31, (3-(2-chloro-6-fluorobenzyl)-imidazolidine-2,4-dione), was recently detected as a potential drug to be used as an adjuvant drug to treat chronic pain. The excellent pharmacological property of PT-31 highlights the importance in elucidating its metabolism, which could provide valuable information about its metabolite profile for further pharmacokinetics studies and additionally to estimate the impact of its metabolites on the efficacy, safety and elimination of PT-31. In this work, the study of the in vitro metabolism of PT-31 was initially carried out by using a liquid chromatography coupled to ion trap multiple-stage mass spectrometer (LC-IT-MSn) and a hybrid triple quadrupole/linear ion trap mass spectrometer (LC-QTrap). The production of at least three unknown oxidative metabolites was observed. Structural identification of the unknown metabolites was carried out by combination of LC-MS experiments, including selected reaction monitoring (SRM) and multi-stage full scan experiments. Further analysis of 1H-NMR led to the structural confirmation of the major metabolite. The results indicated that PT-31 was metabolized by a hydroxylation reaction in the imidazolidine-2,4-dione ring in rat and human liver microsomes, producing the metabolite 3-(2-chloro-6-fluorobenzyl)-5-hydroxyimidazolidine-2,4-dione in rat liver microsomes. A carbon hydroxylation onto the benzyl ring, produced two other minor metabolites of the PT-31 in rat liver microsomes.
Collapse
Affiliation(s)
- Josiane de O Cardoso
- Núcleo de Pesquisa em Cromatografia (Separare), Department of Chemistry, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| | - Bianca F da Silva
- Núcleo de Pesquisa em Cromatografia (Separare), Department of Chemistry, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| | - Tiago Venâncio
- Núcleo de Pesquisa em Cromatografia (Separare), Department of Chemistry, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil
| | - Marina G da Rocha Pitta
- Núcleo de Pesquisa em Inovação Terapêutica (NUPIT), Federal University of Pernambuco, Recife, PE, 50670-901, Brazil
| | - Ivan da R Pitta
- Núcleo de Pesquisa em Inovação Terapêutica (NUPIT), Federal University of Pernambuco, Recife, PE, 50670-901, Brazil
| | - Rosângela G Peccinini
- College of Pharmaceutical Sciences, São Paulo State University, Araraquara, SP, 14801-902, Brazil
| | - Regina V Oliveira
- Núcleo de Pesquisa em Cromatografia (Separare), Department of Chemistry, Federal University of São Carlos, São Carlos, SP, 13565-905, Brazil.
| |
Collapse
|
9
|
Comparison of dexmedetomidine vs. remifentanil combined with sevoflurane during radiofrequency ablation of hepatocellular carcinoma: a randomized controlled trial. Trials 2019; 20:28. [PMID: 30621749 PMCID: PMC6326039 DOI: 10.1186/s13063-018-3010-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 10/20/2018] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Remifentanil is widely used for ultrasound-guided percutaneous radiofrequency ablation (RFA) of small hepatocellular carcinoma (HCC). We determined whether dexmedetomidine could be an alternative to remifentanil for RFA of HCC under general anesthesia with sevoflurane. METHODS We prospectively randomized patients scheduled to undergo RFA for HCC to a dexmedetomidine (DEX) group or remifentanil (REMI) group (47 patients each). In the DEX group, a bolus infusion (0.4 μg kg- 1) was started 15 min before anesthesia induction and continued at 0.2 μg kg- 1 h- 1 until 10 min before the end of surgery. In the REMI group, 3 μg kg- 1 h- 1 of remifentanil was administered from 15 min before anesthesia induction to the end of the surgery. The primary endpoint was postoperative pain intensity. Secondary endpoints included analgesic requirement, postoperative liver function, patient comfort, and hemodynamic changes. Group allocation was concealed from patients and data analysts but not from anesthesiologists. RESULTS Postoperative pain intensity, analgesic consumption, comfort, liver function, and time to emergence and extubation did not differ between the two groups. Heart rate, but not mean arterial pressure, was significantly lower in the DEX group than in the REMI group, at 1 min after intubation and from 30 min after the start of the surgery until anesthesia recovery. Sevoflurane concentration and dosage were significantly lower in the DEX group than in the REMI group. CONCLUSION During RFA for HCC, low-dose dexmedetomidine reduced the heart rate and need for inhalational anesthetics, without exacerbating postoperative discomfort or liver dysfunction. Although it did not exhibit outstanding advantages over remifentanil in terms of pain management, dexmedetomidine could be a safe alternative adjuvant for RFA under sevoflurane anesthesia. TRIAL REGISTRATION Chinese Clinical Trial Registry, ChiCTR-OPC-15006613 . Registered on 16 June 2015.
Collapse
|
10
|
Sudo RT, Hayashida K, Santos AN, Kawatani M, Monteiro CE, Moreira RD, Trachez MM, Montes GC, Zapata-Sudo G. Novel agonist of α 4β 2* neuronal nicotinic receptor with antinociceptive efficacy in rodent models of acute and chronic pain. J Pain Res 2018; 11:2453-2462. [PMID: 30464575 PMCID: PMC6214310 DOI: 10.2147/jpr.s169637] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective To demonstrate the antinociceptive and antihypersensitivity mechanisms of Cris-104 (1-{2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl]ethyl}piperidine), a novel selective α4β2* nicotinic acetylcholine receptor (nAChR) agonist, in rodent acute/inflammatory and chronic pain models. Materials and methods Hot-plate and formalin tests in mice were used to examine Cris-104-induced antinociceptive effects on thermal/inflammatory pain. Cris-104 effects on hypersensitivity, norepinephrine (NE) release in the spinal dorsal horn, and neuronal activity in the locus coeruleus (LC) were examined in rats with lumbar spinal nerve ligation using behavioral, microdialysis, and extracellular recording methods. Cris-104 effects on spontaneous locomotion were examined in an open-field test. Results Cris-104 induced dose-dependent antinociception effects in hot-plate and formalin tests, and these effects were blocked by the general nAChR antagonist mecamylamine, the selective α4β2* nAChR antagonist dihydro-beta-erythroidine, and the α2-adrenoceptor antagonist yohimbine, but not by the α1-adrenoceptor antagonist prazosin. Systemic and spinally perfused Cris-104 increased NE concentrations in microdialysates from the spinal cord in both normal and SNL rats. Systemic Cris-104 increased neuronal activity in the LC of normal rats. Mecamylamine blocked the effects of Cris-104 on spinal NE release and LC neuronal activity. Systemic Cris-104 did not affect locomotor activity significantly. Conclusion The α4β2 neuronal nAChR agonist, Cris-104, was effective for treatment of pain via descending noradrenergic inhibition of pain signaling.
Collapse
Affiliation(s)
- Roberto T Sudo
- Program of Research in Drug Development of Biomedical Science, Institute of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, .,Post-Graduation Program in Medicine (General Surgery) of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| | - Kenichiro Hayashida
- Department of Neurophysiology, Akita University School of Medicine, Akita, Japan
| | - Aluizio N Santos
- Post-Graduation Program in Medicine (General Surgery) of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| | - Masahito Kawatani
- Department of Neurophysiology, Akita University School of Medicine, Akita, Japan
| | - Carlos Es Monteiro
- Program of Research in Drug Development of Biomedical Science, Institute of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| | - Roberto D Moreira
- Cristalia Produtos Quimicos e Farmacêuticos Ltda, Itapira, São Paulo, Brazil
| | - Margarete M Trachez
- Program of Research in Drug Development of Biomedical Science, Institute of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| | - Guilherme C Montes
- Program of Research in Drug Development of Biomedical Science, Institute of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| | - Gisele Zapata-Sudo
- Program of Research in Drug Development of Biomedical Science, Institute of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,
| |
Collapse
|
11
|
Kitanaka N, Kitanaka J, Hall FS, Kandori T, Murakami A, Muratani K, Nakano T, Uhl GR, Takemura M. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex. Pharmacol Biochem Behav 2018; 172:9-16. [PMID: 30017858 DOI: 10.1016/j.pbb.2018.07.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 07/10/2018] [Accepted: 07/11/2018] [Indexed: 10/28/2022]
Abstract
A single administration with morphine (30 mg/kg, i.p.) induced long-lasting hyperlocomotion in male ICR mice. Pretreatment of mice with a benzoquinolizine derivative tetrabenazine (TBZ; a reversible vesicular monoamine transporter-2 inhibitor) (1 mg/kg, i.p.) for 30 min significantly attenuated the hyperlocomotion induced by morphine, as compared with vehicle (saline)-pretreated mice. No significant change in locomotion was observed in mice pretreated with TBZ (1 mg/kg) alone. Mice treated with TBZ (1 mg/kg) showed an increase in immobility time in a tail suspension test, as compared with saline-treated mice. Pretreatment with TBZ (1 mg/kg) had no effect on morphine (1-30 mg/kg)-induced antinociception. TBZ at a dose of 1 mg/kg inhibited dopamine turnover (the ratio of 3,4-dihydroxyphenylacetic acid/dopamine) and 5-hydroxytryptamine turnover (the ratio of 5-hydroxyindoleacetic acid/5-hydroxytryptamine) in the cerebral cortex of mice challenged with morphine, as compared with saline-pretreated mice challenged with morphine. No stereotypic behavior was observed in mice treated with morphine (30 mg/kg) in combination with TBZ (1 mg/kg), so the reduction in observed locomotion did not result from induction of stereotypical behavior. Moreover, TBZ (1 and 2 mg/kg) pretreatment had no effect on stereotyped behaviors observed in mice challenged with 10 mg/kg methamphetamine. These data support the potential antagonistic actions of TBZ on some opiate actions, and encourage further exploration of potential effects on morphine reinforcement.
Collapse
Affiliation(s)
- Nobue Kitanaka
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - Junichi Kitanaka
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan.
| | - F Scott Hall
- Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA
| | - Takashi Kandori
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - Ayaka Murakami
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - Kazuki Muratani
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - Tae Nakano
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - George R Uhl
- New Mexico VA Healthcare System/BRINM, Albuquerque, NM 87108, USA
| | - Motohiko Takemura
- Department of Pharmacology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| |
Collapse
|
12
|
Alencar AK, Carvalho FI, Silva AM, Martinez ST, Calasans-Maia JA, Fraga CM, Barreiro EJ, Zapata-Sudo G, Sudo RT. Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS One 2018; 13:e0195047. [PMID: 29677206 PMCID: PMC5909907 DOI: 10.1371/journal.pone.0195047] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 03/15/2018] [Indexed: 01/08/2023] Open
Abstract
Introduction Pulmonary hypertension (PH) is characterized by enhanced pulmonary vascular resistance, which causes right ventricle (RV) pressure overload and results in right sided heart failure and death. This work investigated the effectiveness of a combined therapy with PDE5 inhibitor (PDE5i) and a new adenosine A2A receptor (A2AR) agonist in mitigating monocrotaline (MCT) induced PH in rats. Methods An in vitro isobolographic analysis was performed to identify possible synergistic relaxation effect between sildenafil and LASSBio 1359 in rat pulmonary arteries (PAs). In the in vivo experiments, PH was induced in male Wistar rats by a single intraperitoneal injection of 60 mg/kg MCT. Rats were divided into the following groups: control (saline injection only), MCT + vehicle, MCT + sildenafil, MCT + LASSBio 1359 and MCT + combination of sildenafil and LASSBio 1359. Fourteen days after the MCT injection, rats were treated daily with oral administration of the regimen therapies or vehicle for 14 days. Cardiopulmonary system function and structure were evaluated by echocardiography. RV systolic pressure and PA endothelial function were measured. Results Isobolographic analysis showed a synergistic interaction between sildenafil and LASSBio 1359 in rat PAs. Combined therapy with sildenafil and LASSBio 1359 but not monotreatment with low dosages of either sildenafil or LASSBio 1359 ameliorated all of PH related abnormalities in cardiopulmonary function and structure in MCT challenged rats. Conclusions The combination of sildenafil and LASSBio 1359 has a synergistic interaction, suggesting that combined use of these pharmacological targets may be an alternative to improve quality of life and outcomes for PH patients.
Collapse
Affiliation(s)
- Allan K. Alencar
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Fábio I. Carvalho
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Ananssa M. Silva
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Sabrina T. Martinez
- Instituto de Química, Universidade Federal Fluminense, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Jorge A. Calasans-Maia
- Serviço de Anestesiologia, Hospital Universitário, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Carlos M. Fraga
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Eliezer J. Barreiro
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Gisele Zapata-Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Roberto T. Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|
13
|
Sudo RT, do Amaral RV, Monteiro CEDS, Pitta IDR, Lima MDC, Montes GC, Ririe DG, Hayashida K, Zapata-Sudo G. Antinociception induced by a novel α 2A adrenergic receptor agonist in rodents acute and chronic pain models. Eur J Pharmacol 2017; 815:210-218. [PMID: 28935564 DOI: 10.1016/j.ejphar.2017.09.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 09/06/2017] [Accepted: 09/14/2017] [Indexed: 01/05/2023]
Abstract
The mechanisms and antinociceptive effects of a novel α2A adrenoceptor agonist, 3-(2-chloro-6-fluorobenzil)-imidazolinide-2,4-dione (PT-31) were investigated using animal models of acute and chronic pain. The effects of PT-31 on pain responses were examined using hot plate and formalin tests in mice and spinal nerve ligation (SNL)-induced hyperalgesia in rats. The effects of antagonists acting on α adrenoceptor were assessed to investigate the interaction of these pathways upon PT-31 induced antinociception. PT-31 effects on motor activity/skills and on hemodynamic parameters were also evaluated. PT-31 had dose-dependent antinociception effects on hot-plate and formalin-injection induced pain responses. Thermal hyperalgesia and mechanical allodynia were reduced following a 7 d treatment with PT-31 (1, 5, and 10mg/kg/d, p.o.), and those effects were attenuated by yohimbine (5mg/kg), atropine (2mg/kg), L-nitro arginine methyl ester (L-NAME; 30mg/kg), or naloxone (2mg/kg). In contrast to clonidine, PT-31 did not have locomotor or hemodynamic effects in rats. The present results suggest that PT-31 represents a candidate for pain treatment with advantages over clonidine, namely no locomotor or hemodynamic impairments.
Collapse
Affiliation(s)
- Roberto Takashi Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil.
| | - Rachel Vieiralves do Amaral
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil
| | - Carlos Eduardo da Silva Monteiro
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil
| | - Ivan da Rocha Pitta
- Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, PE, Brazil
| | - Maria do Carmo Lima
- Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, PE, Brazil
| | - Guilherme Carneiro Montes
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil
| | - Douglas Gordon Ririe
- Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Kenichiro Hayashida
- Department of Neurophysiology, Akita University School of Medicine, Akita, Japan
| | - Gisele Zapata-Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, RJ, Brazil
| |
Collapse
|
14
|
Comparative pharmacodynamic analysis of imidazoline compounds using rat model of ocular mydriasis with a test of quantitative structure–activity relationships. J Pharm Biomed Anal 2017; 144:122-128. [DOI: 10.1016/j.jpba.2017.03.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/08/2017] [Accepted: 03/26/2017] [Indexed: 11/23/2022]
|
15
|
Matos-Rocha TJ, de Lima MDCA, da Silva AL, de Oliveira JF, Gouveia ALA, da Silva VBR, de Almeida ASA, Brayner FA, Cardoso PRG, Pitta-Galdino MDR, Pitta IDR, Rêgo MJBDM, Alves LC, Pitta MGDR. Synthesis and biological evaluation of novel imidazolidine derivatives as candidates to schistosomicidal agents. Rev Inst Med Trop Sao Paulo 2017; 59:e8. [PMID: 28380119 PMCID: PMC5441159 DOI: 10.1590/s1678-9946201759008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 09/22/2016] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION: Schistosomiasis is an infectious parasitic disease caused by trematodes of the genus Schistosoma, which threatens at least 258 million people worldwide and its control is dependent on a single drug, praziquantel. The aim of this study was to evaluate the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives. MATERIAL AND METHODS: We synthesized two novel imidazolidine derivatives: (LPSF/PTS10) (Z)-1-(2-chloro-6-fluorobenzyl)-4-(4-dimethylaminobenzylidene)-5-thioxoimidazolidin-2-one and (LPSF/PTS23) (Z)-1-(2-chloro-6-fluoro-benzyl)-5-thioxo-4-(2,4,6-trimethoxy-benzylidene)-imidazolidin-2-one. The structures of two compounds were determined by spectroscopic methods. During the biological assays, parameters such as motility, oviposition, mortality and analysis by Scanning Electron Microscopy were performed. RESULTS: LPSF/PTS10 and LPSF/PTS23 were considered to be active in the separation of coupled pairs, mortality and to decrease the motor activity. In addition, LPSF/PTS23 induced ultrastructural alterations in worms, after 24 h of contact, causing extensive erosion over the entire body of the worms. CONCLUSION: The imidazolidine derivatives containing the trimetoxy and benzylidene halogens showed promising in vitro schistosomicidal activity.
Collapse
Affiliation(s)
- Thiago José Matos-Rocha
- Fundação Oswaldo Cruz (Fiocruz/PE), Centro de Pesquisas Aggeu Magalhães, Laboratório de Biologia Celular e Molecular, Recife, Pernambuco, Brazil
- Universidade Federal de Pernambuco, Laboratório de Imunopatologia Keizo Asami, Recife, Pernambuco, Brazil
- Universidade Federal de Pernambuco, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisas em Inovação Terapêutica Suely Galdino, Recife, Pernambuco, Brazil
| | - Maria do Carmo Alves de Lima
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Anekécia Lauro da Silva
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Jamerson Ferreira de Oliveira
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Allana Lemos Andrade Gouveia
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Vinícius Barros Ribeiro da Silva
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Antônio Sérgio Alves de Almeida
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Fábio André Brayner
- Fundação Oswaldo Cruz (Fiocruz/PE), Centro de Pesquisas Aggeu Magalhães, Laboratório de Biologia Celular e Molecular, Recife, Pernambuco, Brazil
- Universidade Federal de Pernambuco, Laboratório de Imunopatologia Keizo Asami, Recife, Pernambuco, Brazil
| | - Pablo Ramon Gualberto Cardoso
- Universidade Federal de Pernambuco, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisas em Inovação Terapêutica Suely Galdino, Recife, Pernambuco, Brazil
| | - Marina da Rocha Pitta-Galdino
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Ivan da Rocha Pitta
- Universidade Federal de Pernambuco, Laboratório de Planejamento e Síntese de Fármacos (LPSF), Departamento de Antibióticos, Recife, Pernambuco, Brazil
| | - Moacyr Jesus Barreto de Melo Rêgo
- Universidade Federal de Pernambuco, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisas em Inovação Terapêutica Suely Galdino, Recife, Pernambuco, Brazil
| | - Luiz Carlos Alves
- Fundação Oswaldo Cruz (Fiocruz/PE), Centro de Pesquisas Aggeu Magalhães, Laboratório de Biologia Celular e Molecular, Recife, Pernambuco, Brazil
- Universidade Federal de Pernambuco, Laboratório de Imunopatologia Keizo Asami, Recife, Pernambuco, Brazil
| | - Maira Galdino da Rocha Pitta
- Universidade Federal de Pernambuco, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisas em Inovação Terapêutica Suely Galdino, Recife, Pernambuco, Brazil
| |
Collapse
|
16
|
Bessegato TC, Niehues M, Buqui GA, Lopes NP, Pitta IR, Galdino SL, Dalla Costa T. Development and validation of a UHPLC-MS/MS bioanalytical method to quantify in plasma the analgesic candidate PT-31 following a preliminary pharmacokinetic study in rats. Biomed Chromatogr 2015; 30:852-6. [DOI: 10.1002/bmc.3618] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 07/16/2015] [Accepted: 09/14/2015] [Indexed: 11/09/2022]
Affiliation(s)
- T. C. Bessegato
- Programa de Pós-Graduação em Ciências Farmacêuticas; Universidade Federal do Rio Grande do Sul; Porto Alegre RS Brazil
| | - M. Niehues
- Núcleo de Pesquisa de Produtos Naturais e Sintéticos; Universidade de São Paulo; Ribeirão Preto SP Brazil
| | - G. A. Buqui
- Núcleo de Pesquisa de Produtos Naturais e Sintéticos; Universidade de São Paulo; Ribeirão Preto SP Brazil
| | - N. P. Lopes
- Núcleo de Pesquisa de Produtos Naturais e Sintéticos; Universidade de São Paulo; Ribeirão Preto SP Brazil
| | - I. R. Pitta
- Núcleo de Pesquisa em Inovação Terapêutica; Universidade Federal de Pernambuco; Recife PE Brazil
| | - S. L. Galdino
- Núcleo de Pesquisa em Inovação Terapêutica; Universidade Federal de Pernambuco; Recife PE Brazil
| | - T. Dalla Costa
- Programa de Pós-Graduação em Ciências Farmacêuticas; Universidade Federal do Rio Grande do Sul; Porto Alegre RS Brazil
| |
Collapse
|
17
|
Sudo RT, Neto ML, Monteiro CE, Amaral RV, Resende ÂC, Souza PJ, Zapata-Sudo G, Moura RS. Antinociceptive effects of hydroalcoholic extract from Euterpe oleracea Mart. (Açaí) in a rodent model of acute and neuropathic pain. Altern Ther Health Med 2015; 15:208. [PMID: 26134625 PMCID: PMC4489033 DOI: 10.1186/s12906-015-0724-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 06/15/2015] [Indexed: 11/10/2022]
Abstract
Background Plants rich in flavonoids, such as açaí (Euterpe oleraceae Mart.), can induce antinociception in experimental animals. Here, we tested an extract obtained from the stones of açaí fruits (açaí stone extract, ASE), a native plant from the Amazon region of Brazil, in models of acute/inflammatory and chronic pain. Methods Antinociceptive effects of ASE were evaluated in the hot plate, formalin, acetic acid writhing, carrageenan, and neuropathic pain models, as well as in thermal hyperalgesia and mechanical allodynia models induced by spinal nerve ligation. Antinociceptive activities were modulated by the administration of cholinergic, adrenergic, opioid, and L-arginine-NO antagonists. Results Oral administration of ASE (30, 100, or 300 mg.kg−1) dose-dependently reduced nociceptive responses to acute/inflammatory pain in mice, including thermal hyperalgesia, acetic acid-induced writhing, and carrageenan-induced thermal hyperalgesia. Moreover, ASE reduced the neurogenic and inflammatory phases after intraplantar injection of formalin in mice. The antinociceptive effect of ASE (100 mg · kg−1) in a hot plate protocol, was inhibited by pre-treatment with naloxone (1 mg · kg−1), atropine (2 mg · kg−1), yohimbine (5 mg · kg−1), or L-NAME (30 mg · kg−1). Furthermore, ASE prevented chronic pain in a rat spinal nerve ligation model, including thermal hyperalgesia and mechanical allodynia. Conclusion ASE showed significant antinociceptive effect via a multifactorial mechanism of action, indicating that the extract may be useful in the development of new analgesic drugs.
Collapse
|
18
|
de Queiroz RB, de Carvalho FL, Fonsêca DVD, Barbosa-Filho JM, Salgado PRR, Paulo LL, de Queiroz ABM, Pordeus LCDM, de Souza SA, Souza HDDS, Lira BF, de Athayde-Filho PF. Antinociceptive effect of hydantoin 3-phenyl-5-(4-ethylphenyl)-imidazolidine-2,4-dione in mice. Molecules 2015; 20:974-86. [PMID: 25580690 PMCID: PMC6272532 DOI: 10.3390/molecules20010974] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Accepted: 01/05/2015] [Indexed: 11/23/2022] Open
Abstract
Imidazolidine derivatives, or hydantoins, are synthetic compounds with different therapeutic applications. Many imidazolidine derivatives have psychopharmacological properties, such as phenytoin, famous for its anticonvulsant efficacy, but also effective in the treatment of neuropathic pain. The hydantoin, 3-phenyl-5-(4-ethylphenyl)-imidazolidine-2,4-dione (IM-3), synthesized from the amino acid, glycine, was selected for psychopharmacological studies in mice on the basis of its chemical and structural similarity with phenytoin. The first step of this study was to define the LD50, which determined the doses of 50, 100 and 200 mg/kg for subsequent tests. The results obtained from the behavioral screening indicated that IM-3 produces decreased ambulation and analgesia in mice. Motor coordination and anxiety behavior were not affected by treatment with IM-3, as observed in the rotarod and elevated plus-maze tests, respectively. Regarding its antinociceptive properties, IM-3 showed efficacy in the acetic acid-induced writhing test by increasing the latency of the first writhe and reducing the number of writhes, as well as reducing the paw licking time in the second phase of the formalin test. The behavior of treated animals exposed to the hot plate test, however, did not differ from that of the control group. These data suggest that IM-3 has antinociceptive effects in mice, which is probably mediated by anti-inflammatory mechanisms.
Collapse
Affiliation(s)
| | | | - Diogo Vilar da Fonsêca
- Center for Health Sciences, Federal University of Paraiba, João Pessoa PB 58059-900, Brazil.
| | | | | | - Luciano Leite Paulo
- Center for Health Sciences, Federal University of Paraiba, João Pessoa PB 58059-900, Brazil.
| | | | | | | | | | - Bruno Freitas Lira
- Department of Chemistry, Federal University of Paraiba, João Pessoa PB 58059-900, Brazil.
| | | |
Collapse
|
19
|
Stolz ED, Hasse DR, von Poser GL, Rates SMK. Uliginosin B, a natural phloroglucinol derivative, presents a multimediated antinociceptive effect in mice. J Pharm Pharmacol 2014; 66:1774-85. [DOI: 10.1111/jphp.12307] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 06/29/2014] [Indexed: 12/18/2022]
Abstract
Abstract
Objective
Investigate the involvement of monoaminergic and glutamatergic systems on the antinociceptive and ataxic effects of uliginosin B, which we have already demonstrated to be a promising molecular scaffold to develop new analgesic drugs.
Methods
Uliginosin B was obtained from hexane extract of aerial parts of Hypericum polyanthemum by chromatographic methods. Uliginosin B antinociceptive and motor coordination effects were evaluated in mice by using hot-plate (15 and 90 mg/kg, i.p.) and rotarod (90 mg/kg, i.p.) tests, respectively. The mechanism of action was investigated through pretreatments with prazosin 1 mg/kg intraperitoneal (α1 receptor antagonist), yohimbine 5 mg/kg intraperitoneal (α2 receptor antagonist), pCPA 300 mg/kg intraperitoneal (serotonin synthesis inhibitor) and MK-801 0.25 mg/kg intraperitoneal (N-methyl-D-aspartic acid receptor antagonist).
Key findings
The antinociceptive effect of uliginosin B (15 and 90 mg/kg, i.p.) was reduced significantly by pCPA and MK-801. Prazosin and yohimbine improved the antinociceptive effect of the highest dose (90 mg/kg, i.p.) of uliginosin B only. The ataxic effect of uliginosin B (90 mg/kg, i.p.) was completely prevented by pretreatment with pCPA or MK-801, but it was unaffected by pretreatment with prazosin or yohimbine.
Conclusion
These data confirm the contribution of monoaminergic neurotransmission as well as provide the first evidence of glutamatergic neurotransmission contribution to the uliginosin B effects.
Collapse
Affiliation(s)
- Eveline Dischkaln Stolz
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Diego Rafael Hasse
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Gilsane Lino von Poser
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Stela M K Rates
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
20
|
Cheung CW, Qiu Q, Ying ACL, Choi SW, Law WL, Irwin MG. The effects of intra-operative dexmedetomidine on postoperative pain, side-effects and recovery in colorectal surgery. Anaesthesia 2014; 69:1214-21. [PMID: 24915800 DOI: 10.1111/anae.12759] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/01/2014] [Indexed: 12/15/2022]
Abstract
In this double-blind, randomised study, 100 patients undergoing open or conventional laparoscopic colorectal surgery received an intra-operative loading dose of dexmedetomidine 1 μg.kg(-1) followed by an infusion of 0.5 μg.kg(-1) .h(-1) , or a bolus and infusion of saline 0.9% of equivalent volume. Forty-six patients in the dexmedetomidine group and 50 in the saline group completed the study. The area under the curve of numerical rating scores for pain at rest for 1-48 h postoperatively was significantly lower in the patients receiving dexmedetomidine (p = 0.041). There was no difference in morphine consumption, duration of recovery ward or hospital stay. From the data obtained in this study, we calculated a number needed to treat for effective pain relief of 4. Intra-operative dexmedetomidine in colorectal surgery resulted in a reduction in resting pain scores, but there was no morphine-sparing effect or improvement in patients' recovery outcome measures.
Collapse
Affiliation(s)
- C W Cheung
- Laboratory and Clinical Research Institute for Pain, Department of Anaesthesiology, The University of Hong Kong, Hong Kong, China
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
In the last decade, preclinical investigations of electroacupuncture mechanisms on persistent tissue injury (inflammatory), nerve injury (neuropathic), cancer, and visceral pain have increased. These studies show that electroacupuncture activates the nervous system differently in health than in pain conditions, alleviates both sensory and affective inflammatory pain, and inhibits inflammatory and neuropathic pain more effectively at 2 to 10 Hz than at 100 Hz. Electroacupuncture blocks pain by activating a variety of bioactive chemicals through peripheral, spinal, and supraspinal mechanisms. These include opioids, which desensitize peripheral nociceptors and reduce proinflammatory cytokines peripherally and in the spinal cord, and serotonin and norepinephrine, which decrease spinal N-methyl-D-aspartate receptor subunit GluN1 phosphorylation. Additional studies suggest that electroacupuncture, when combined with low dosages of conventional analgesics, provides effective pain management which can forestall the side effects of often-debilitating pharmaceuticals.
Collapse
Affiliation(s)
- Ruixin Zhang
- Assistant Professor, Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, Maryland
| | - Lixing Lao
- Professor, Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, Maryland
| | - Ke Ren
- Professor, Department of Neural and Pain Sciences, Dental School, University of Maryland, Baltimore, Maryland
| | - Brian M. Berman
- Professor, Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, Maryland
| |
Collapse
|
22
|
Evaluation of the anti-Schistosoma mansoni activity of thiosemicarbazones and thiazoles. Antimicrob Agents Chemother 2013; 58:352-63. [PMID: 24165185 DOI: 10.1128/aac.01900-13] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Schistosomiasis is a chronic and debilitating disease caused by a trematode of the genus Schistosoma and affects over 207 million people. Chemotherapy is the only immediate recourse for minimizing the prevalence of this disease and involves predominately the administration of a single drug, praziquantel (PZQ). Although PZQ has proven efficacy, there is a recognized need to develop new drugs as schistosomicides since studies have shown that repeated use of this drug in areas of endemicity may cause a temporary reduction in susceptibility in isolates of Schistosoma mansoni. Hydrazones, thiosemicarbazones, phthalimides, and thiazoles are thus regarded as privileged structures used for a broad spectrum of activities and are potential candidates for sources of new drug prototypes. The present study determined the in vitro schistosomicidal activity of 10 molecules containing these structures. During the assays, parameters such motility and mortality, oviposition, morphological changes in the tegument, cytotoxicity, and immunomodulatory activity caused by these compounds were evaluated. The results showed that compounds formed of thiazole and phthalimide led to higher mortality of worms, with a significant decline in motility, inhibition of pairing and oviposition, and a mortality rate of 100% starting from 144 h of exposure. These compounds also stimulated the production of nitric oxide and tumor necrosis factor alpha (TNF-α), thereby demonstrating the presence of immunomodulatory activity. The phthalyl thiazole LpQM-45 caused significant ultrastructural alterations, with destruction of the tegument in both male and female worms. According to the present study, phthalyl thiazole compounds possess antischistosomal activities and should form the basis for future experimental and clinical trials.
Collapse
|
23
|
Bhalla S, Ali I, Andurkar SV, Gulati A. Centhaquin antinociception in mice is mediated by α2A- and α2B- but not α2C-adrenoceptors. Eur J Pharmacol 2013; 715:328-36. [DOI: 10.1016/j.ejphar.2013.05.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 04/25/2013] [Accepted: 05/05/2013] [Indexed: 10/26/2022]
|
24
|
Abstract
This paper is the thirty-third consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2010 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration (Section 16); and immunological responses (Section 17).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, Flushing, NY 11367, USA.
| |
Collapse
|
25
|
Anti-inflammatory and antinociceptive activities of indole-imidazolidine derivatives. Int Immunopharmacol 2011; 11:1816-22. [PMID: 21855654 DOI: 10.1016/j.intimp.2011.07.010] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2011] [Revised: 07/15/2011] [Accepted: 07/15/2011] [Indexed: 12/21/2022]
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) represent a group of approximately 50 different medicines that are widely prescribed for the management of inflammation and that exhibit variable anti-inflammatory, anti-pyretic and analgesic activities. Most NSAIDs also exhibit a shared set of adverse effects, particularly related to gastrointestinal complications; thus, the development of new drugs for the treatment of chronic inflammation and pain continues to be an issue of high interest. Hydantoin and indole derivatives are reported to possess various pharmacological effects, including anti-inflammatory and analgesic activities. Therefore, the aim of this study was to evaluate the potential anti-inflammatory and antinociceptive activities of hybrid molecules containing imidazole and indole nuclei. The anti-inflammatory activities of 5-(1H-Indol-3-yl-methylene)-2-thioxo-imidazolidin-4-one (LPSF/NN-56) and 3-(4-Bromo-benzyl)-5-(1H-indol-3-yl-methylene)-2thioxo-imidazolidin-4-one (LPSF/NN-52) were evaluated using air pouch and carrageenan-induced peritonitis models as well as an acetic acid-induced vascular permeability model followed by IL-1β and TNF-α quantification. To evaluate the antinociceptive activities of the compounds, acetic acid-induced nociception, formalin and hot plate tests were also performed. The anti-inflammatory activities of the compounds were evidenced by a reduction in both leukocyte migration and the release of TNF-α and IL-1β in air pouch and peritonitis models. Upon acetic acid-induced nociception, a decrease in the level of abdominal writhing in the groups treated with LPSF/NN-52 (52.1%) or LPSF/NN-56 (63.1%) was observed. However, in the hot plate test, none of the derivatives tested exhibited an inhibition of nociception. These results indicate that the compounds tested exhibited promising anti-inflammatory and antinociceptive activities that likely involved the modulation of the immune system.
Collapse
|